Signal #129471 · SEC 8-K

$URGN SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $URGN filing catalyst

Why did $URGN trigger an AI stock catalyst alert?

$URGN triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: UroGen Pharma Reports Q3 2026 Revenue Surge to $89.0M, Slashes Net Loss to $1.5M. Key points: - Total Q3 revenue reached $89.0M vs. $27.5M YoY, with ZUSDURI product revenue up 35% QoQ to $68.0M. - Net loss narrowed significantly to $1.5M ($0.03/share) compared to $33.3M ($0.69/share) in Q3 2025. - Operating income turned positive at $8.3M; cash and equivalents stood at $90.5M.

How did $URGN stock react after the SEC filing?

After the SEC 8-K for $URGN, observed market reaction: T0 price $34.40. Past moves do not guarantee future results.

Where can I get real-time $URGN SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $URGN via Telegram and the VIP Web Terminal from €10/month.

$URGN

$URGN – UroGen Pharma Reports Q3 2026 Revenue Surge to $89.0M, Slashes Net Loss to $1.5M

UroGen Pharma Ltd.

2026-11-04 00:00:00 UTC · SEC 8-K · All $URGN

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

Total Q3 revenue reached $89.0M vs. $27.5M YoY, with ZUSDURI product revenue up 35% QoQ to $68.0M.
Net loss narrowed significantly to $1.5M ($0.03/share) compared to $33.3M ($0.69/share) in Q3 2025.
Operating income turned positive at $8.3M; cash and equivalents stood at $90.5M.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →